The new oral anticoagulants and the future of haemostasis laboratory testing

@inproceedings{Favaloro2012TheNO,
  title={The new oral anticoagulants and the future of haemostasis laboratory testing},
  author={Emmanuel J Favaloro and Giuseppe Lippi},
  booktitle={Biochemia medica},
  year={2012}
}
The tests currently employed within most haemostasis laboratories to monitor anticoagulant therapy largely comprise the prothrombin time (PT)/ International Normalised Ratio (INR) and the activated partial thromboplastin time (APTT). These are respectively used to monitor Vitamin K antagonists (VKAs) such as warfarin, and unfractionated heparin. Additional tests that laboratories may also employ for assessing or monitoring unfractionated heparin include thrombin time (TT) and the anti-Xa assay… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

Anticoagulant therapy and its impact on dental patients: a review.

Australian dental journal • 2016
View 4 Excerpts
Highly Influenced

Dental management of patients on anti-thrombotic agents

Journal of the Korean Association of Oral and Maxillofacial Surgeons • 2018

Management of novel oral anticoagulants in emergency and trauma surgery.

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland • 2016
View 3 Excerpts

Anticoagulant therapy: present and future.

Seminars in thrombosis and hemostasis • 2015

References

Publications referenced by this paper.
Showing 1-10 of 42 references

Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis • 2012

Dabigatran etexilate: A novel oral direct thrombin inhibitor.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists • 2011

Similar Papers

Loading similar papers…